Individualizing treatment with atypical antipsychotics: Factors to consider in decision making

Drug Benefit Trends

Volumn 14, Issue SUPPL. E, 2002, Pages 24-31

  Nelson, Matthew ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic agents; Pharmacotherapy; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

AGE; AGGRESSION; AGITATION; ALGORITHM; ANOVULATION; BEHAVIOR DISORDER; BONE DEMINERALIZATION; BREAST DISEASE; BREAST DYSPLASIA; BREAST HYPERPLASIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOXICITY; EJACULATION DISORDER; ENDOTHELIUM INJURY; ERECTILE DYSFUNCTION; ESTROGEN DEFICIENCY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GENDER; GENERAL CONDITION IMPROVEMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPOGONADISM; IMPOTENCE; INDIVIDUALITY; INFERTILITY; LIBIDO DISORDER; MEDICAL DECISION MAKING; MEMORY DISORDER; MENSTRUATION DISORDER; ORGASM DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPATHY; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 0036959572     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Guideline for Atypical Antipsychotic Use. Washington, DC: Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel, Veterans Health Administration, Dept of Veterans Affairs; 2002.
2. Chiles JA, Miller AL, Crismon ML, et al. The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatr Serv. 1999;50:69-74.
3. Garthwaite TL. Guidance concerning the prescribing of atypical antipsychotic medications. VHA Notice 2002-01. Washington, DC: Dept of Veterans Affairs, Veterans Health Administration; January 16, 2002.
4. Statement of the Honorable Thomas L. Garthwaite, MD, Under Secretary for Health, Veterans Health Administration, before the Subcommittee on Health, Committee on Veterans Affairs, US House of Representatives. June 20, 2001.
5. Frances A, Doherty JP, Kahn DA, eds. The Expert Consensus Guideline Series: Treatment of schizophrenia. J Clin Psychiatry. 1996;57(suppl 12B):3-58.
6. McEvoy JP, Scheifler PL, Frances A, eds. Expert Consensus Guideline Series: Treatment of schizophrenia. J Clin Psychiatry. 1999;60(suppl 11):1-80.
7. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.
8. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry. 1999;60(suppl 10):5-14.
9. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57-73.
10. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999;9:301-309.
11. Cupp MJ, Tracy TS. Cytochrome P450: New nomenclature and clinical implications. Am Fam Physician. 1998;57:107-116.
12. Dresser GK, Spencer JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
13. Gaw AC. Concise Guide to Cross-Cultural Psychiatry. Washington, DC: American Psychiatric Publishing, Inc; 2001.
14. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51:317-324.
15. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649-1671.
16. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in schizophrenia, I: Definitions, epidemiology and acute treatment. Essent Psychopharmacol. 2002;5:1-16.
17. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61(suppl 3):4-9.
18. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183-190.
19. Glazer WM. Formulary decisions and health economics. J Clin Psychiatry. 1998;59(suppl 19):23-29.
20. Collaborative Working Group on Clinical Trial Evaluation. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry. 1998;59 (supp 12):41-45.
21. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
22. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249-258.
23. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999;156:863-868.
24. Moore DB, Kelly DL, Sherr JD, et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: Comparison with risperidone. Am J Health Syst Pharm. 1998;55(suppl 4):S17-S19.
25. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991;266:2402-2406.
26. Kane JM, Woerner MG, Lieberman J, et al. Tardive dyskinesia and drugs. Drug Dev Res. 1986;9:41-51.
27. Gerlach J. Improving outcome in schizophrenia: The potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry. 2002;14:47-57.
28. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86.
29. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
30. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
31. Keskiner A, El-Toumi A, Bousquet T. Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics. 1973;14:176-181.
32. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia: A preliminary study. J Clin Hosp Pharm. 1986;11:297-299.
33. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68-73.
34. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
35. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: Clinical and regulatory implications: Report on a policy conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216-1231.
36. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 1993;72:23B-25B.
37. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation. London: European Agency for the Evaluation of Medicinal Products; December 17, 1997. CPMP Report 986/96.
38. De Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: The Rotterdam Study. Circulation. 1998;97:467-472.